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Background: Rheumatoid arthritis (RA) is a chronic autoinflammatory joint disease which leads to the destruction
of joints and disability of the patients. Anti-tumour necrosis factor (anti-TNF) drugs can halt radiological progression
better than conventional DMARDs even in clinical non-responders.
Methods: The efficacy of anti-TNF plus methotrexate (MTX) treatment versus MTX monotherapy on clinical and
radiological outcomes were compared in early rheumatoid arthritis (RA) patients in clinical practice by retrospective
analysis of an observational cohort.
49 early RA patients (group A) on first-line MTX monotherapy and 35 early RA patients (group B) on anti-TNF plus
MTX treatment were selected from an observational cohort and evaluated retrospectively focusing on their first
twelve months of treatment. Data on disease activity (DAS28) and functional status (HAQ-DI) were collected three
monthly. One-yearly radiological progression was calculated according to the van der Heijde modified Sharp
method (vdHS). Clinical non-responder patients in both groups were selectively investigated from a radiological
point of view.
Results: Disease activity was decreased and functional status was improved significantly in both groups. One-yearly
radiological progression was significantly lower in group B than in group A. The percentage of patients showing
radiological non-progression or rapid radiological progression demonstrated a significant advantage for group B
patients. In addition non-responder patients in group B showed similar radiological results as responders, while a
similar phenomenon was not observed in patients in group A.
Conclusions: Clinical efficacy within our study was similar for tight-controlled MTX monotherapy as well as for
combination treatment with anti-TNF and MTX. However MTX monotherapy was accompanied by more rapid
radiological progression and less radiological non-progression. Anti-TNF plus MTX decreased radiological
progression even in clinical non-responders supporting the advantage of anti-TNF plus MTX combination in
dissociating clinical and radiological effects.
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Rheumatoid arthritis (RA) is a chronic systemic inflam-
matory musculoskeletal disease that represents a signifi-
cant health burden both with regard to comorbidities as
well as to the mortality of patients [1,2]. The chronic
inflammation and destruction of synovial joints leads to
functional impairment, work loss and progressive dis-
ability [3]. In the past deeper insights into the patho-
genesis of RA has led to the introduction of biologic
agents and subsequently to considerable changes in the
management of RA with respect to preventing and con-
trolling disease progression [4]. The in-depth under-
standing of the disease course and the increasing data
of treatment strategies supported the development of
widely accepted recommendations on the management
and therapy of the disease [5,6]. Clinical remission, pre-
vention of joint destruction and long-term disability
have emerged as the primary goals of modern treatment
for RA [5].
The concept of the ‘window of opportunity’ supports
that early agressive treatment can significantly change
the long-term course of the disease, resulting in higher
clinical response rates, less disability and less erosive
damage [7,8]. Biological agents have proven to be effec-
tive in patients responding insufficiently to MTX in ran-
domised controlled trials (RCTs), not only in reducing
disease activity and improving functional status, but
in slowing radiological progression [9-15]. Monoclonal
antibodies against TNF including adalimumab, etaner-
cept and infliximab, and lately the interleukin-6 receptor
inhibitor tocilizumab and anti-CD20 rituximab preven-
ted joint destruction even in patients failing to show a
clinical response to MTX monotherapy [16-20]. Such
“dissociation” between disease activity and radiological
progression appears to be an additional advantage of
biologics.
To the best of our knowledge as of yet the phe-
nomenon of dissociation was evaluated only in RCTs,
with selected patient populations and not in routine
clinical care. Our aim was to examine how anti-TNF +
MTX therapy affect clinical, functional and radiological
outcomes – primarily focusing on dissociation - com-
pared with MTX monotherapy in early RA patients in
routine care.
Methods
As part of the ABRAB (Assessment of Biologics in
Rheumatoid Arthritis in Budapest) study, a retrospective
analysis of an observational cohort, adult (≥18 years)
early RA patients (diagnosed ≤2 years) from the obser-
vational cohort of the outpatient clinic of the National
Institute of Rheumatology and Physiotherapy, Budapest
was performed. All patients were diagnosed according to
the 1987 American College of Rheumatology criteria[21]. Patients were selected randomly based on the avail-
ability of baseline and 12 month radiographs of hands and
feet in order to calculate radiological progression after
12 month. High baseline disease activity (DAS28 ≥ 5.1)
was also among the selection criteria. Approval of the
Ethics Committee of National Institute of Rheumatology
and Physiotherapy in Budapest was given prior to the
study, and informed consent was obtained from all
patients.
We grouped selected patients into two groups: patients
in group A (n = 49) received first-line MTX monotherapy
(10–20 mg weekly) with no previous DMARDs, while
those in group B (n = 35) received anti-TNF +MTX
(10–20 mg weekly) treatment. Patients in group B were
treated with the following agents: infliximab (20%), etaner-
cept (22,9%), adalimumab (40%), golimumab (14,2%) and
certolizumab (2,9%). All anti-TNFs were administrated ac-
cording to the method of administration indicated in the
summary of product characteristics. All patients in group
B failed one or two prior DMARDs according to local
guidelines on the use of biologics in RA.
Patients in both groups were treated in routine care.
All patients had erosive disease, as documented by
having at least one erosion on baseline hands and feet
X-rays.The baseline characteristics of the two treatment
groups were comparable and shown in Table 1.
Clinical data was recorded at five timepoints during
the first 12 months of treatment in both groups (at 0, 3,
6, 9 and 12 month). Disease activity was measured by
DAS28 based on the erythrocyte sedimentation rate and
by CDAI (clinical disease activity index), functional sta-
tus was determined using HAQ-DI score. We evaluated
the efficacy of anti-TNF +MTX treatment and MTX
monotherapy in reducing disease activity and improving
functional status in both groups in the first 12 month of
their investigated treatment period, and also compared
the differences between their data. The ratio of patients
reaching the state of remission or low disease activity
was also determined in both groups. Remission was
defined as DAS28 < 2.6 or CDAI ≤2,8 and low disease ac-
tivity was defined as DAS28 ≤ 3.2 and ≥2.6 or CDAI ≤10
and ≥2.9. [5].
All patients had hands and feet radiographs at baseline
and at the end of the 12th month treatment period.
Radiological progression was measured according to the
van der Heijde modified Sharp method (vdHS; 0–448
points) on radiographs of the hands and feet. All radio-
graphs were scored by three readers, a radiologist and
two rheumatologists (AM, JB, PJ) blinded to patient
identity, treatment and the date of the radiographs.
Radiological values given by agreement of the three
readers were used for the analysis. As a consequence of
routine clinical care, the interval between the two dif-
ferent radiographic timepoints were for some patients
Table 1 Baseline demographic and disease
characteristics*
Group A (n = 49)
(MTX treatment)
% v. mean (SD)
Group B (n = 35)
(anti-TNF +MTX
treatment) %
v. mean (SD)
Age, (mean ± S.D.) 60.1 (13.7) 54.7 (15)
Women, n (%) 42 (85.7%) 28 (80%)
Disease duration, (month) 7.9 (2) 8.5 (1.2)
IgM RF positive, n (%) 34 (69.4%) 22 (62.9%)
Anti-CCP positive, n (%) 37 (75.5%) 26 (74.3%)
DAS28ESR , mean ± S.D. 6.1 (0.9) 6.4 (0.9)
CDAI, mean ± S.D. 36.2 (11.5) 33.6 (12.7)
Tender joint count, mean ± S.D. 13.1 (6.5) 14 (7.2)
Swollen joint count, mean ± S.D. 7.5 (5.9) 9.4 (5.2)
Patient global assessment (VAS
0–100), mean ± S.D.
65 (17.9) 64.3 (18.3)
ESR, mean ± S.D. 43.7 (22.4) 46.9 (33.5)
CRP, mean ± S.D. 27.5 (28.4) 40.3 (46.9)
HAQ-DI (0–3), mean ± S.D. 1.4 (0.7) 1.6 (0.7)
*There were no statistically significant differences in any demographic or
baseline characteristics between the groups, by Mann–Whitney test for
continuous variables and chi-square test for dichotomous variables; statistical
significance was set as p < 0.05.
(RF: rheumatoid factor, anti-CCP: anti-cyclic citrullinated protein, DAS28ESR:
disease activity score based on the erythrocyte sedimentation rate, CDAI: clinical
disease activity index, VAS: visual analogue scale, ESR: erythrocyte sedimentation
rate, CRP: C-reactive protein, HAQ-DI: Health Assessment Questionnaire - Disability
Index, vdHS: van der Heijde modified Sharp score).
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radiological progression at 12 months (vdHS U/year)
was calculated dividing the change in the radiological
score with the ratio of the real time interval and the as-
sumed 12 months. The impact on radiological progres-
sion was compared between the different treated groups,
and in addition the ratio of patients with no radiological
progression (vdHS = 0 U/year) and those showing rapid
radiological progression (vdHS ≥ 5 U/year) was alsoFigure 1 Disease activity (DAS28) at 0, 3, 6, 9 and 12 months in grou
***: p < 0,001.compared between the two groups [22]. To investigate
the dissociation between reduction of disease activity
and impact on radiological progression in groups, radio-
logical progression at 12 months as well as the ratio of
radiological non-progression and that of rapid radio-
logical progression was compared in patients who failed
to show a clinical response. Clinical non-response was
defined as a time-averaged DAS28 ≥ 3.2. The time-aver-
aged DAS28 was calculated as the mean DAS28 of visits
at month 3, 6, 9 and 12.
Statistical analysis was performed with Graphpad
Prism 5.00 statistical software. The distribution of the
variables is provided as mean ± SD. We used the inde-
pendent two-tailed Student’s t-test and paired t-test to
compare continuous variables between and in groups.
We used either Mann–Whitney or Wilcoxon matched
pairs test for non-parametric data, while one-way or re-
peated measures ANOVA with corresponding post-tests
(Tukey’s or Dunnet’s multiple comparison) was used for
comparing three or more variables. We used Fisher’s
exact test to compare dichotomous variables between
groups and considered p < 0.05 as statistically significant.
Results
Disease activity reduction
Mean disease activity (DAS28) was significantly reduced
compared to the baseline mean value at all visits both in
group A and group B (p < 0.001). From the month 3 visit
onward, no further significant improvement was observed
in either group (Figure 1). Mean disease activity reduction
was greater in number at all visits for group B, but sig-
nificant differences were found only between the 0–6 and
0–9 month timepoints when comparing both groups.
Reaching DAS28 remission and the state of low
disease activity
There was no significant difference in the percentage of
patients reaching DAS28 or CDAI remission or lowp A and group B. (mean, 25&75 percentiles and min.- max. values)
Table 2 Number and percentage of patients showing
radiological non-progression or rapid radiological
progression in group A and group B
Group A
(n = 49)
Group B
(n = 35)
p-value
Radiological non-progression n(%) 9 (18.4%) 19 (54.3%) ***
Rapid radiological progression n (%) 9 (18.4%) 0 (0%) **
***: p < 0.001; **: p < 0.01.
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visits (data not shown). At 12 months 15 (30.6%) and 11
(31.4%) patients showed DAS28 remission, 9 (18,37%)
and 8 (22,86%) patients showed CDAI remission in
group A and B respectively, with an additional 7 (14.3%)
and 5 (14.3%) patient achieving DAS28 low disease ac-
tivity, 19 (38,77%) and 17 (48,57%) patients achieving
CDAI low disease activity respectively.
Functional status improvement
The mean functional status (HAQ-DI) was significantly
reduced compared to the baseline mean value at all visits
both in group A and group B (p < 0.001). Similarly to
disease activity, we could not observe a significant im-
provement after 3 months (data not shown).
Overall radiological results
Using the vdHS scoring method the mean yearly radio-
logical progression was 3.177 (3.453) U/year in group A
(95% CI 2.185-4.169) and 0.7071 (1.117) U/year in group
B (95% CI 0.3234-1.091) with statistically significant dif-
ference (p < 0.001) as shown in Figure 2. The percentage
of patients showing rapid radiological progression
(vdHS/year ≥ 5 U/year) or radiological non-progression
(vdHS/year = 0 U/year) is shown in Table 2. None of the
patients in group B showed rapid radiological pro-
gression. Radiological progression was halted in a high
percentage (n = 19, 54,3%) of these patients, which was
statistically significantly different to as compared to pa-
tients in group A (p < 0.001).
Radiological progression in clinical responders and
non-responders
To perform a more detailed evaluation of radiological
progression at 12 months patients in both treated groups
were divided into subgroups of clinical non-responder
and clinical responder patients. A non-significant trendFigure 2 Radiological progression (vdHS U/year) at 12 months
in group A and group B. (mean, 25&75 percentiles and min.- max.
values) ***: p < 0,001.was observable in group A showing that radiological pro-
gression was higher in clinical non-responders than in
clinical responders when compared to all patients within
that group. This suggests the persistant effect of disease
activity on radiological progression on MTX monothe-
rapy. In group B we observed no difference in radiological
progression at 12 months between responders and non-
responders, indicating that anti-TNF +MTX treatment
indeed dissociates disease activity and radiological pro-
gression (Figure 3).
Radiological progression at 12 months and the percent-
age of patients showing radiological non-progression or
rapid radiological progression were separately assessed in
the subgroups of clinically non-responder patients. Within
these subgroups mean radiological progression was 3.698
(3.837) U/year (95% CI: 2.337-5.058) in group A and
0.7141 (1.26) U/year (95% CI: 0.066-1.362) in group B
(p < 0.001, Figure 4). Group B was associated with a higher
percentage of patients with radiological non-progression
than group A (58.8% vs 12.1% respectively, p < 0.001). We
found no significant difference regarding rapid radio-
logical progression, nevertheless group B showed betterFigure 3 Change in radiological progression (vdHS U/year) in
group A and group B regarding all, clinical non-responder and
clinical responder patients. (All: all patients, Resp: clinical responder
patients, Non-resp: clinical non-responder patients).
Figure 4 Radiological progression at 12 months (vdHS U/year)
of clinical non-responders (time-averaged DAS28 > 3.2) in
group A and group B. (mean, 25&75 percentiles and min.- max.
values) ***: p < 0.001.
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respectively, p = 0.07).
Discussion
We evaluated early RA patients under different treat-
ment in routine rheumatological outpatient care and
showed comparable clinical efficacy of anti-TNF +MTX
and MTX monotherapy in the first 12 month of treat-
ment. Both groups had significant improvement in
DAS28 reduction which was noticeable at the 3 months
visit, and was sustained along the observed 12 months
treatment period. The value of DAS28 reduction was
higher at all visits in the anti-TNF +MTX treated group,
and was significant at 3 months. The percentage of
patients achieving DAS28 remission as the desirable
therapeutic goal in RA [5], was comparable between the
anti-TNF +MTX and MTX monotherapy treated groups,
despite the higher DAS28 reduction in the former group.
The rate of remission at month 12 was 31.4% in the anti-
TNF +MTX treated group consistent with data found in
the literature on patients treated in clinical practice
[23,24]. Similar rates of DAS28 remission in the MTX-
treated group (30.6%) can be explained by the early, tight
controlled design of the treatment.
Functional status (HAQ-DI) was significantly improved
in both groups from month 3 and was sustained along the
observed 12-month treatment period, with no clear dif-
ferences between the two groups. Functional disability, as
measured by HAQ-DI has been shown to have two
components. The irreversible component correlates with
radiological status, mainly cartilage destruction and sub-
luxation, and worsens with time. The reversible domain is
related to disease activity and can be therapeutically in-
fluenced [25,26]. Our observed groups had comparable
baseline radiological status as well as comparableimprovement of clinical activity that explains the similar
effect of anti-TNF +MTX and MTX monotherapy on
functional status.
There is strong evidence on the efficacy of anti-TNF +
MTX vs. MTX monotherapy in slowing/halting radiological
progression [9-13]. Comparing the two groups, anti-TNF +
MTX treated patients had significantly less radiological pro-
gression than those treated with MTX monotherapy. Our
data confirms the superiority of anti-TNF +MTX treatment
not only in decreasing radiological progression, but also in
inhibiting rapid radiological progression and increasing the
rate of radiological non-progression. The high percentage
of radiological non-progression in the anti-TNF +MTX
treated group indicates marked clinical success since the in-
vestigated patients had baseline radiographic damage and
anti-CCP positivity in high percentage that are the main
predictive factors of poor radiologic outcome [27].
Erosions of the joints and cartilage destruction are hall-
marks of RA. Formerly, it was conceptualized that in RA
inflammation leads directly to the destruction of bone and
cartilage. Recently we have learned that bone destruction
is intricately linked to the RANKL (receptor activator of
nuclear factor kB ligand)-OPG (osteoprotegerin) system
which is strongly, but not exclusively connected to the in-
flammatory processes occurring within the joint [28]. The
disbalance between RANKL and OPG mainly determines
the degree of proliferation and activity of osteoclasts in
RA. Osteoblasts produce both RANKL and OPG, the ratio
of which is influenced by hormones, growth factors and
many cytokines, among them TNF-alpha [28]. The strong
inhibitory effect of anti-TNFs on radiological progression
may be explained by their direct inhibitory effects
on osteoclast activity, in addition to their overall anti-
inflammatory effect [16].
RCTs (randomized controlled trials) comparing anti-
TNFs +MTX to MTX support the phenomenon of disso-
ciation between inflammation and radiological progression,
which may explain the slowing/halting of radiological pro-
gression in the absence of a clinical response [16-18]. Dis-
sociation may potentially be explained by the threshold
hypothesis, which assumes that TNF-driven osteoclast
activation occurs only when the level of TNF reaches a
putative threshold. In case of clinical and radiological dis-
sociation anti-TNF therapy decreases the level of TNF
below this threshold, but not low enough to cease the in-
flammatory activity as well [29]. This assumes that inflam-
mation is sustained at lower levels of TNF than at levels at
which osteoclast activation occurs. Recent analysis from the
PREMIER trial showed that the dissociation between cli-
nical and radiological outcomes (joint space narrowing and
joint erosions) at week 52 and 104 occurred in patients
treated with adalimumab (ADA) +MTX but only to a mild
degree in patients on ADA monotherapy [30], which might
indicate that MTX may enchance the dissociative potential
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IL-6 inhibition with tocilizumab [19] and with anti-CD20
rituximab therapy [20], A recent meta-analysis of intensive
DMARD combination therapy with step-down predni-
solone study also suggested a similar phenomenon in
patients [31].
Nevertheless, there are some limitations to our clinical
study. Firstly the anti-TNF +MTX treated group re-
ceived preliminary DMARDs that decreases compara-
bility with the DMARD naїve MTX treated patients.
Secondly the X-ray examinations for calculating radio-
logical progression were made not exactly at the 12th
month of treatment which could have minimally dis-
torted the value of radiological progression at 12 months
assumed as linear in the analysis. Thirdly the relatively
low number of early RA cases with available X-rays, es-
pecially in a subanalysis may have reduced the statistical
power of our calculations. All of these limitations stem
from the fact that our analysed patients were treated in
routine clinical care and according to the local guide-
lines, DMARD treatment is mandatory before starting
anti-TNFs. Additionally the use of hands and feet X-rays
for following radiological disease progression is not
regular in routine care, especially not at exactly a time
interval of 12 month: the fact that the availability of
X-rays at two timepoints was an inclusion criteria may
have indeed introduced a selection bias into our study.Conclusions
Our results prove the superiority of anti-TNF +MTX
therapy in dissociating inflammation and radiologic des-
truction. Anti-TNF +MTX treatment strongly inhibited
radiological progression even in patients not reaching clin-
ical remission or low disease activity. Not only therapeutic
responders, but also non-responders of the combination
group showed better radiologic results than patients on
MTX monotherapy. Our data indicates that even if anti-
TNF +MTX treatment is only partly successful in achieving
remission or low disease activity, it can inhibit radiographic
damage.
Anti-TNF +MTX treatment strongly inhibited radio-
logical progression even in patients not reaching clinical
remission or low disease activity. Further “real-life” investi-
gations are needed in the future to evaluate the impact of
anti-TNF +MTX treatment on clinical and radiological
dissociation in routine clinical practice.
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